D. Fleishaker

发表

Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children

M. Hilty, J. Bruss, K. Wible, 2003, The Pediatric infectious disease journal.

Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients

D. M. van der Heijde, A. Deodhar, S. Sherlock, 2018, Rheumatology.

Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study

F. Whaley, D. Fleishaker, B. Zeiher, 2016, BMC Musculoskeletal Disorders.

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

C. Mebus, T. Stock, D. Fleishaker, 2012, Arthritis Research & Therapy.

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

A. Orbai, P. Mease, O. FitzGerald, 2022, BMC Rheumatology.

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

D. M. van der Heijde, A. Deodhar, T. Hendrikx, 2016, Annals of the rheumatic diseases.

SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

L. Coates, D. Gladman, P. Mease, 2018, Saturday, 16 JUNE 2018.

FRI0509 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study

T. Hendrikx, P. Nash, A. Kivitz, 2017 .

In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF‐00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor

T. Stock, H. Eng, D. Fleishaker, 2017, Clinical pharmacology in drug development.

Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial

V. Strand, J. Cappelleri, M. Magrey, 2022, RMD Open.

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

D. M. van der Heijde, Huji Xu, A. Deodhar, 2021, Annals of the Rheumatic Diseases.

POS1020 EFFICACY OF TOFACITINIB ON DACTYLITIS IN INDIVIDUAL DIGITS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

A. Orbai, P. Mease, O. FitzGerald, 2021 .

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

L. Coates, D. Gladman, P. Mease, 2020, Rheumatology and Therapy.

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

L. Coates, D. Gladman, P. Mease, 2019, The Lancet Rheumatology.

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study

L. Coates, D. Gladman, P. Mease, 2021 .

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib

P. Nash, V. Azevedo, L. Bessette, 2021, Rheumatology and Therapy.

OP0002 Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study

D. M. van der Heijde, D. Li, A. Deodhar, 2016 .

Improved disease activity with fosdagrocorat (PF‐04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study

C. Mebus, T. Stock, D. Fleishaker, 2017, International journal of rheumatic diseases.

Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children

S. Kaplan, J. Bruss, D. Fleishaker, 2003, The Pediatric infectious disease journal.

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

B. Strober, D. Gladman, A. Yndestad, 2022, Therapeutic advances in musculoskeletal disease.

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial

M. Østergaard, W. Maksymowych, Cunshan Wang, 2023, Rheumatology and Therapy.

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies

A. Orbai, P. Mease, O. FitzGerald, 2023, Arthritis Research & Therapy.